Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 3 5Phase 1/2 5Phase 2/3 4Phase NA 3Phase 4 2Phase 1 2Phase EARLY_PHASE1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Solid Tumor 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × disitamab vedotin × Clear all
NCT05940896 2023-11-27

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

RemeGen Co., Ltd.

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

NCT06078982 2023-10-12

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Shanghai East Hospital

Phase 1 Unknown
39 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡